Страна: Канада
Език: английски
Източник: Health Canada
MIRTAZAPINE
RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
N06AX11
MIRTAZAPINE
30MG
TABLET
MIRTAZAPINE 30MG
ORAL
100
Prescription
MISCELLANEOUS ANTIDEPRESSANTS
Active ingredient group (AIG) number: 0143928002; AHFS:
CANCELLED POST MARKET
2014-09-19
_Page 1 of 31_ PRODUCT MONOGRAPH Pr ratio-MIRTAZAPINE 30 mg tablets Antidepressant ratiopharm inc. DATE OF PREPARATION: 17 800 rue Lapointe August 26, 2005 Mirabel, PQ J7J 1P3 Control #: 100745 _Page 2 of 31_ Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION..............................................................3 SUMMARY PRODUCT INFORMATION..............................................................................3 INDICATIONS AND CLINICAL USE....................................................................................3 CONTRAINDICATIONS.........................................................................................................3 WARNINGS AND PRECAUTIONS........................................................................................3 ADVERSE REACTIONS.........................................................................................................7 DRUG INTERACTIONS........................................................................................................12 DOSAGE AND ADMINISTRATION....................................................................................13 OVERDOSAGE.......................................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY...................................................................14 STORAGE AND STABILITY................................................................................................17 DOSAGE FORMS, COMPOSITION AND PACKAGING...................................................17 PART II: SCIENTIFIC INFORMATION......................................................................................18 PHARMACEUTICAL INFORMATION................................................................................18 CLINICAL TRIALS................................................................................................................20 DETAILED PHARMACOLOGY........................................................................ Прочетете целия документ